BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34687175)

  • 21. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
    Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
    [No Abstract]   [Full Text] [Related]  

  • 22. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impairment of HIF-1α-mediated metabolic adaption by NRF2-silencing in breast cancer cells.
    Lee S; Hallis SP; Jung KA; Ryu D; Kwak MK
    Redox Biol; 2019 Jun; 24():101210. PubMed ID: 31078780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
    Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
    Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancer-bound Nrf2 licenses HIF-1α transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells.
    Jin X; Gong L; Peng Y; Li L; Liu G
    Aging (Albany NY); 2020 Dec; 13(1):364-375. PubMed ID: 33290263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fructose-1,6-Bisphosphatase 1 Reduces
    Chen R; Li J; Zhou X; Liu J; Huang G
    Radiology; 2017 Sep; 284(3):844-853. PubMed ID: 28387640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
    Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
    Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.
    Takaki H; Hirata Y; Ueshima E; Kodama H; Matsumoto S; Wada R; Suzuki H; Nakasho K; Yamakado K
    J Vasc Interv Radiol; 2020 Sep; 31(9):1475-1482.e2. PubMed ID: 32800663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma.
    Shimizu T; Inoue K; Hachiya H; Shibuya N; Aoki T; Kubota K
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):467-71. PubMed ID: 27246794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
    Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
    J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LncRNA HOTAIR knockdown inhibits glycolysis by regulating miR-130a-3p/HIF1A in hepatocellular carcinoma under hypoxia.
    Hu M; Fu Q; Jing C; Zhang X; Qin T; Pan Y
    Biomed Pharmacother; 2020 May; 125():109703. PubMed ID: 32062551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis.
    Méndez-Blanco C; Fernández-Palanca P; Fondevila F; González-Gallego J; Mauriz JL
    Ther Adv Med Oncol; 2021; 13():1758835920987071. PubMed ID: 33613697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
    Calderaro J; Rousseau B; Amaddeo G; Mercey M; Charpy C; Costentin C; Luciani A; Zafrani ES; Laurent A; Azoulay D; Lafdil F; Pawlotsky JM
    Hepatology; 2016 Dec; 64(6):2038-2046. PubMed ID: 27359084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
    Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
    Front Immunol; 2018; 9():2077. PubMed ID: 30254644
    [No Abstract]   [Full Text] [Related]  

  • 37. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
    El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
    Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
    Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
    J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.